BioAdaptives® Inc. (OTC: BDPT), developer of the Xcellara™ line of stem cell mobilization supplements, today announced the upcoming commercial availability of XcellaraHeart™, a premium cardiovascular ...

Amyloid oligomers — not plaques — may be the true neurotoxic driver of Alzheimer's disease, and ProMIS Neurosciences now has ...

Scientists have kept donated human retinas responsive to light for up to 10 hours after death, marking a significant advance ...

If that growth materializes, there's enough upside for Circle stock to double within the next four years.

Ford has rehired experienced human engineers to help address the shortcomings of artificial intelligence (AI) tools meant to tackle quality issues in the automaker's production processes. The hiring ...

Scientists have taken a surprising step toward unlocking regeneration in mammals, showing that the ability to rebuild complex body parts may not be lost after all—it may simply be switched off. Using ...

Dr. J. Mikhail Kellawan received his BSc (Honors) from the University of Guelph (Guelph, Ontario, Canada) and his MSc from the University of Victoria (Victoria, British Columbia, Canada). He completed ...

Doxorubicin cardiomyopathy (DoxCM) remains a significant clinical problem, but its underlying mechanisms remain incompletely understood. Identifying DoxCM mechanisms can lead to therapeutic ...

While humans evolved to perform routine endurance activity, recent secular trends in the United States and globally have resulted in a dramatic rise in the amount of time spent inactive in both ...